Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

Nov 13, 2018

|

This story has been updated to include comments from Biocept's earnings call with analysts.

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Tuesday that its third quarter 2018 revenues plunged 31 percent year over year as total test volumes shrank 28 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocept Q3 Revenues Drop 31 Percent as Test Volume Shrinks

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

What's Popular?

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Abviris Developing Blood-Based Serology Test For HPV-Related Cancers

Ginkgo Bioworks Collaborating With Access Bio on COVID-19 Antigen Tests

Sponsorships